GlassScriptPhysician profile
James John Ivanoski
NPI 1922166826
$1,420.91
in general payments reported to CMS, 2019-2025
15 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $156 · 2021: $164 · 2022: $422 · 2023: $93.85 · 2024: $362 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.33 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $241.85 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $186.02 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $179.95 | 2020-2022 | |
| Horizon Therapeutics Plc | $165.80 | 2022-2023 | Tepezza |
| Abbvie INC. | $131.15 | 2023-2025 | |
| Biotissue Holdings INC. | $89.79 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $86.00 | 2019-2024 | Cequa |
| Oyster Point Pharma, INC. | $79.32 | 2022-2024 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $72.17 | 2022-2025 | Hydrus Microstent, Eysuvis |
| Bausch & Lomb Americas INC. | $62.68 | 2023-2024 | Vyzulta, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.64 | 2019-2021 | |
| Harrow Eye, LLC | $25.84 | 2024 | Vevye |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $14.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ivanoski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.